Alnair Investment

Alnair Therapeutics is a preclinical-stage biotechnology company developing a proprietary platform for the targeted delivery of therapeutics to solid tumors. The company's "smart" nanoparticle technology is designed to respond to the unique physiological conditions of the tumor microenvironment, such as acidity (pH), to release drugs specifically within cancer cells. This approach aims to improve the therapeutic index of potent anti-cancer agents while minimizing systemic toxicity. Alnair's lead programs focus on difficult-to-treat indications, including glioblastoma and other advanced solid tumors, by targeting metabolic vulnerabilities like lactate transport. The company was founded by experts in drug delivery and oncology to translate precision medicine into effective clinical outcomes.